
Shaun Verma
Founder & CEO, iksa
Bio
I'm the founder and CEO of iksa, the harness for n-of-1 medicine, built to run clinical trial grade medicine for individuals. I've been a founder since 2009 and spent over fifteen years in healthcare, the last decade of it in software.
Most of that decade was spent inside clinical trials. I've run trials with seven of the top 10 pharma companies and restructured how they run from phase I through phase IV, and I changed how four of the top 10 report patient-reported outcomes and adverse events on their phase IV trials. On the software those trials run on, I owned the roadmap for a leading clinical trial management system and built the one for an AI product in adaptive trial design.
iksa began as software for running registries for real-world evidence, with pilots at many of the top pharma companies, and that work led me to concierge medicine through the Hopkins network. This medicine asks for far more than a regular prescription does. A refill reminder and a survey carry a patient through most medications, but here patients inject themselves and stack five or six therapies personalized to them, from peptides to stem cells, over years. Their doctor opens with a two-hour consultation and a nurse team follows them the whole way, because these clinics live on retention and the level of care matters more to them than the time it takes. Each of those patients is a clinical trial of one, run on individual cash-pay economics, and that is what iksa is built for.
I founded my first health organization, MDJunior, at fourteen. When the Thiel Fellowship offered me a place, I said no and went to Hopkins.
I'm from Atlanta and based in Baltimore. I love jazz and my goldendoodle Ted.
Thesis
Personalized medicine is changing the way healthcare is manufactured, delivered, and consumed, and it starts with Longevity.
Over time, I've watched the burden of disease impact healthcare's effort to build a digitized continuum of care. In traditional care models the loop is split across parties: the payer pays for the visit, the provider delivers it, the patient manages much of what happens between visits, and outcomes often live somewhere else entirely. Most healthcare software still behaves a bit like a filing cabinet, very good at storing what happened in the visit, much less useful for managing the months of care around it.
Longevity may be one of the first models where the incentives actually support that continuum. The patient is the customer, care happens through protocols lasting months, and whether the patient gets a result is closely tied to whether they stay engaged.
We believe in a future of medicine where every personalized protocol is chosen from evidence of what worked for patients like this one.
Articles
Why the Industry Is Calling Personalized Medicine “Longevity”
Precision medicine was defined to include prevention, and longevity medicine is that prevention half, practiced over years.
Longevity Medicine Outgrew Its Software
The best longevity clinics are practicing longitudinal, protocol-driven care on software built for discrete visits.
Transforming Chronic Care Management Through Adaptive AI
Talks
“AI Platforms for Clinical Care”, panel at the NYC AI x Longevity Summit, BioLabs at NYU Langone, June 2026
Insight Partners’ inaugural Product Ops Summit
Portfolio
iksa
The harness for n-of-1 medicine.
Clinical AI in Health System
An eight-month study across 538 patients and 15 physicians, where medication adherence rose from 50% to 88%, and a patent applied for on its graph-based machine learning.
Clinical trial software
Roadmaps for a leading clinical trial management system and an AI product in adaptive trial design.
Trials and drug pricing
Patient-reported outcomes and adverse-event reporting at four of the top 10 life sciences organizations, and pricing across a top-10 pharma company's 116 drugs.
India's vaccine supply chain
With the United Nations Development Programme in New Delhi, now across 27,000 cold-chain points in 29 states.
MDJunior
16+ medical missions, 10,000+ patients cared for, 50+ chapters in eight countries and $2M+ in grassroots impact.
Global Youth Health Summit
Started in 2015 at Emory University, and still running.
Longevity Global
Director of the Baltimore chapter.
My passion has always been the data model, the breadth and depth of it, the conceptual semantics and the granular quantitative proof. That's what drove me to build my first agent with GPT-2, apply for a patent around our graph harness with my team in 2024, and today has gotten weekly volume to 2,495 contributions per week with ~24 billion tokens. Over 1,100 agent sessions weekly running 99% autonomously.
Contact
I advise life sciences companies and health systems on data models and AI. For advisory engagements, speaking invitations and other inquiries, please use the form below.
To request a walkthrough of iksa for your clinic, please visit iksa.ai.